{"id":56289,"date":"2026-02-04T22:50:24","date_gmt":"2026-02-04T14:50:24","guid":{"rendered":"https:\/\/flcube.com\/?p=56289"},"modified":"2026-02-04T22:50:26","modified_gmt":"2026-02-04T14:50:26","slug":"akeso-licenses-yixining-to-jumpcan-for-pcsk9-promotion-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56289","title":{"rendered":"Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China"},"content":{"rendered":"\n

Akeso Biopharma<\/strong> (HKG: 9926<\/a>) announced a partnership with Jumpcan Pharmaceutical<\/strong> (SHA: 600566<\/a>) granting Jumpcan exclusive promotion rights to Yixining (ebronucimab)<\/strong> in mainland China. Jumpcan will pay Akeso a RMB\u202f80\u202fmillion licensing fee<\/strong> and up to RMB\u202f10\u202fmillion in milestone payments<\/strong>, taking responsibility for commercialization, promotion, and sales.<\/p>\n\n\n\n

Partnership Structure & Drug Profile<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Akeso Biopharma (9926.HK)<\/td><\/tr>
Licensee<\/strong><\/td>Jumpcan Pharmaceutical (600566.SH)<\/td><\/tr>
Asset<\/strong><\/td>Yixining (ebronucimab)<\/td><\/tr>
Rights<\/strong><\/td>Exclusive promotion rights in mainland China<\/td><\/tr>
Financial Terms<\/strong><\/td>RMB\u202f80\u202fM licensing fee + up to RMB\u202f10\u202fM milestone<\/td><\/tr>
Mechanism<\/strong><\/td>PCSK9 inhibitor (blocks PCSK9-LDLR binding, increases LDLR surface expression)<\/td><\/tr>
Approval<\/strong><\/td>China approval Sept\u202f2024; included in NRDL<\/td><\/tr>
Indication<\/strong><\/td>Primary hypercholesterolemia and mixed dyslipidemia<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Commercial Outlook<\/h2>\n\n\n\n